Skip to main content
Premium Trial:

Request an Annual Quote

Rebus Biosystems Closes $20M Series B Financing Round

NEW YORK – Rebus Biosystems, most recently known as Optical Biosystems, announced Thursday it has closed a $20 million Series B financing round, led by Illumina Ventures.

Lifecore Partners, Ncore Ventures, Xolon Invest, CTK Investments, Ray, Seegene Medical Foundation, LabGenomics, and Timefolio Asset Management joined the round.

"The ability of [Rebus Biosystems'] technology to increase throughput, without compromising biological fidelity, will offer spatial analysis to researchers throughout the scientific community," Illuminva Ventures Partners Tom Willis said in a statement.

The Santa Clara, California-based firm's technology includes the patented synthetic aperture optics (SAO) system, which can detect labeled gene transcripts with high-resolution imaging. Founded in 2006 by current CTO Josh Ryu and others, the firm has also been called Solametrix and LightSpeed Genomics. In previous incarnations, the firm has attempted to apply the technology to next-generation sequencing and gene expression analysis.

Rebus Biosystems said it plans to launch its instrument and assay kits for spatial transcriptomics in early 2021.

Illumina Ventures has also participated in funding rounds this year for Stilla Technologies, Genome Medical, and DNA Script.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.